Edesa Biotech Prepares for Key Upcoming Conferences in 2024
Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company, is dedicated to tackling immuno-inflammatory diseases through its cutting-edge research and development. As part of its proactive approach to stakeholder engagement, the company announced its participation in several significant upcoming conferences.
Details of the Upcoming Conferences
Edesa's management and business development teams will represent the company at the following notable events:
BIO-Europe 2024
This leading biotechnology conference will take place in Stockholm, Sweden, from November 4-6, 2024. The event will provide an excellent platform for Edesa to connect with industry peers, investors, and potential partners.
Dermatology Drug Development Summit
Scheduled for November 12-14, 2024, in Boston, this summit focuses on advancements in dermatological drug development. Edesa will highlight its innovative approaches to addressing dermatological conditions, including vitiligo and allergic contact dermatitis.
LSX Investival Showcase
The LSX Investival Showcase in London, UK, on November 18, 2024, offers an opportunity for Edesa to present its scientific developments to a tailored audience of investors and industry leaders.
Strategic Engagement and Meeting Arrangements
Edesa Biotech invites conference attendees to schedule meetings with their team to discuss collaboration opportunities and insights regarding the latest advancements in biopharmaceuticals. Interested parties can reach out to the company or the conference organizers directly. For more information, please contact Edesa at investors@edesabiotech.com.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. specializes in developing novel treatments aimed at inflammatory and immune-related illnesses. The company's clinical pipeline spans two main areas: Medical Dermatology and Respiratory therapeutics. In Medical Dermatology, Edesa is advancing EB06, a monoclonal antibody targeting CXCL10 to combat vitiligo, a challenging autoimmune condition characterized by skin depigmentation.
Additionally, Edesa has prepared EB01, a 1.0% daniluromer cream, which is nearing Phase 3 trials aimed at treating moderate-to-severe allergic contact dermatitis. In the Respiratory sector, EB05 (paridiprubart), under evaluation in a U.S. government-funded study, is focused on Acute Respiratory Distress Syndrome (ARDS), a critical form of respiratory failure. The government of Canada has also provided funding to further develop this promising candidate.
Furthermore, Edesa is in the process of submitting an Investigational New Drug Application (IND) for EB07 (paridiprubart), which will support a future Phase 2 study in pulmonary fibrosis patients, showcasing the company’s dedication to addressing severe respiratory conditions.
Connect With Edesa Biotech
Stay updated with Edesa Biotech's groundbreaking work by signing up for news alerts. Engage with the company on social media platforms such as X and LinkedIn.
Frequently Asked Questions
What is Edesa Biotech, Inc. known for?
Edesa Biotech, Inc. is recognized for developing innovative treatments for immuno-inflammatory diseases, focusing on Medical Dermatology and Respiratory conditions.
Which conferences will Edesa attend?
Edesa will be participating in BIO-Europe, the Dermatology Drug Development Summit, and the LSX Investival Showcase in 2024.
How can I meet with Edesa during these conferences?
Individuals interested in meeting with Edesa during the conferences should contact the company via their email or the conference organizers.
What products are in Edesa's clinical pipeline?
Edesa's pipeline includes EB06 for vitiligo, EB01 for allergic contact dermatitis, and EB05 for ARDS, with additional projects in development for pulmonary fibrosis.
How can I stay updated on Edesa's developments?
You can sign up for news alerts from Edesa Biotech or follow them on social media platforms for the latest updates.
